July 29, 2019

REV•1 Engineering® Named As Exclusive Development Partner For Valvublator

Leonhardt Ventures taps REV•1 Engineering to design and develop Valvublator’s heart valve regeneration technology platform. MURRIETA, Calif. – July 26, 2019 – REV•1 Engineering has been selected as the exclusive design and development partner for the commercialization of Valvublator’s advanced, combination drug/device/biologics technology for regenerating human heart valves.  Valvublator’s platform integrates mechanical, electrical, therapeutical, and biological elements in a single, minimally invasive catheter to decalcify, cell sod and regenerate a patient’s heart valve leaflets.  It is intended […]
July 29, 2019

How Design For Manufacturing Can Effect Company Valuation At Exit

Throughout a medical device’s Life Cycle, few opportunities ever afford themselves to the organization to initiate a strategic approach to Design for Manufacturing in order to optimize product profitability.  This is especially true for companies navigating the transition from clinical stage to commercial stage operations.  The pressure to get to market and begin generating revenue is fierce.  A device that has successfully cleared FDA/secured CE mark, and demonstrated its merits in clinical studies, is going […]
June 25, 2019

Are You Missing The Low Hanging Fruit?

As medical device company executives, it can be challenging to identify opportunities for performance improvement that can quickly and efficiently drive incremental profits to the bottom line.  New product development can often take years to successful launch into the marketplace, not to mention being highly capital intensive.  Expanding sales and marketing, also expensive, can also take time to gain traction.  These two strategic levers share a similarity, they both have a cost, tied to per […]
May 30, 2019
REV.1 Engineering catheter device development.

Developing Medical Devices in an Age of Reimbursement Uncertainty

Developing advanced medical devices is challenging enough even during the most predictable of times.  Today, we’re still in mid-migration, from the traditional, fee-for-service system to a value-based reimbursement system.  Simultaneously, a noteworthy percentage of our nation’s electorate and presidential candidates are debating various versions of a single payer system.  Our industry cousins in the pharmaceutical trades are also finding their pricing coming under greater scrutiny.  Yet, with change comes opportunity. I believe it can be […]
X
Schedule a Conversation
Contact Us